1161921-93-2

Basic information

• Product Name: Benzonitrile, 4-formyl-3-(methylsulfonyl)-
• Synonyms: Benzonitrile, 4-formyl-3-(methylsulfonyl)-;4-formyl-3-(methylsulfonyl)benzonitrile
• CAS NO: 1161921-93-2
• Molecular Formula: C₉H₇NO₃S
• Molecular Weight: 209.22178
• EINECS: -0
• Mol File: 1161921-93-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 468.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Benzonitrile, 4-formyl-3-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-formyl-3-(methylsulfonyl)-(1161921-93-2)
• EPA Substance Registry System: Benzonitrile, 4-formyl-3-(methylsulfonyl)-(1161921-93-2)

Safety Data

• Hazardous Substances Data: 1161921-93-2(Hazardous Substances Data)

Usage

General Description

Benzonitrile, 4-formyl-3-(methylsulfonyl) is a chemical compound that is primarily used in organic synthesis. It is a derivative of benzonitrile, with a formyl group at the 4th position and a methylsulfonyl group at the 3rd position. Benzonitrile, 4-formyl-3-(methylsulfonyl)- has potential applications in drug development, as it can be used to create various functional groups and building blocks for pharmaceuticals. It is also used in the production of agrochemicals and can act as an intermediate in the synthesis of other organic compounds. Additionally, it may have uses in research and industrial processes, where its unique properties can be leveraged for specific applications.

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 20277-69-4 sodium methansulfinate 
• 105942-10-7 3-fluoro-4-formylbenzonitrile 
• 1161921-91-0 4-methyl-3-(methylsulfonyl)benzonitrile 
• 170572-49-3 2-fluoro-4-cyanotoluene 
• 1161921-92-1 4-[2-(dimethylamino)vinyl]-3-(methylsulfonyl)benzonitrile 

Downstream Products

• 1164203-57-9 (rac)-Ethyl 4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 1161921-50-1 (rac)-4-{5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}-3-(methylsulfonyl)benzonitrile 
• 1248520-96-8 allyl 4-[4-cyano-2-(methylsulfanyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 1248520-97-9 (4S)-4-[4-cyano-2-(methylsulfanyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 
• 1248520-98-0 (4S)-4-[4-cyano-2-(methylsulfanyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 
• 1164202-04-3 (rac)-4-{6-(2-Hydroxyethyl)-2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-d]pyrimidin-4-yl}-3-(methylsulfonyl)benzonitrile 
• 1164202-08-7 (rac)-4-{6-Ethyl-2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-d]pyrimidin-4-yl}-3-(methylsulfonyl)benzonitrile 
• 1164202-12-3 (rac)-N-(2-{4-[4-Cyano-2-(methylsulfonyl)phenyl]-2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4,5,7-hexahydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl}ethyl)acetamide 
• 1164202-14-5 (rac)-1-(2-{4-[4-Cyano-2-(methylsulfonyl)phenyl]-2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4,5,7-hexahydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl}ethyl)urea 
• 1161921-98-7 4-[4-cyano-2-(methylsulfanyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 
• 1161921-99-8 (4S)-4-[4-cyano-2-(methylsulfanyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 
• 1164204-45-8 (rac)-Ethyl 6-(bromomethyl)-4-[4-cyano-2-(methylsulfonyl)phenyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 1161921-51-2 4-{(4S)-5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}-3-(methylsulfonyl)benzonitrile 
• 1164201-98-2 (4S)-4-{4-cyano-2-[(S)-methylsulfinyl]phenyl}-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 

Relevant articles and documents

USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE

The invention relates to methods for treating chronic lung disease, in particular, alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency, with a neutrophil elastase inhibitor. The invention further relates to pharmaceut

METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE

The present invention concerns a new and improved method for preparation of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I), as well as the preparation a

TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD

The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.